Hemostatic treatment used for patients with acquired hemophilia A
| Hemostatic treatment modality . | Total no. of patients treated (%) . | No. of patients treated with only this agent (%) . |
|---|---|---|
| None | 51 (34.2) | — |
| FEIBA | 49 (32.9) | 25 (16.8) |
| rFVIIa | 47 (31.5) | 21 (14.1) |
| Human FVIII | 38 (25.5) | 15 (10.1) |
| Desmopressin | 7 (4.7) | 2 (1.3) |
| Porcine FVIII | 3 (1.3) | 0 (0) |
| Hemostatic treatment modality . | Total no. of patients treated (%) . | No. of patients treated with only this agent (%) . |
|---|---|---|
| None | 51 (34.2) | — |
| FEIBA | 49 (32.9) | 25 (16.8) |
| rFVIIa | 47 (31.5) | 21 (14.1) |
| Human FVIII | 38 (25.5) | 15 (10.1) |
| Desmopressin | 7 (4.7) | 2 (1.3) |
| Porcine FVIII | 3 (1.3) | 0 (0) |
The number and proportion of patients treated with each hemostatic agent is shown. Some patients received more than 1 hemostatic agent. Data were not collected on response to hemostatic agents. Although many patients received human factor VIII, in most cases this treatment was used to confirm the diagnosis of acquired hemophilia A by demonstrating a decreased recovery and half-life, or it was given at presentation before other, more suitable, treatments became available. Porcine factor VIII was not readily available in the United Kingdom at the time of the study.
— indicates not applicable.